Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

Objective: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...

Full description

Bibliographic Details
Main Authors: Marzieh Nosrati, Nikinaz Ashrafi Shahmirzadi, Monireh Afzali, Pardis Zaboli, Hasti Rouhani, Haleh Hamedifar, Mirhamed Hajimiri
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Family Medicine and Primary Care
Subjects:
cost-effectiveness
economic evaluation
endothelin receptor antagonists
markov
quality-adjusted life years
sensitivity analysis
Online Access:http://www.jfmpc.com/article.asp?issn=2249-4863;year=2020;volume=9;issue=7;spage=3634;epage=3638;aulast=Nosrati

Internet

http://www.jfmpc.com/article.asp?issn=2249-4863;year=2020;volume=9;issue=7;spage=3634;epage=3638;aulast=Nosrati

Similar Items